The angiotensin-converting enzyme¹¹ angiotensin-converting enzyme
ACE cleaves angiotensin I into angiotensin II (a potent vasoconstrictor) and inactivates bradykinin (a vasodilator). It sits at the centre of the renin-angiotensin-aldosterone system (RAAS) governing blood pressure, fluid balance, and vascular tone gene contains one of the most studied variants in exercise genetics — and this entry covers the variant itself, not its proxy. rs1799752 is the actual 287-base-pair Alu repeat insertion/deletion in intron 16 of ACE; it is the causal variant that drives the differences in circulating and tissue ACE activity. The tag SNP rs4341 (already in the GeneOps database) is a C/G single-nucleotide variant in near-complete linkage disequilibrium with this locus and is used when direct structural genotyping is unavailable. Where a WGS-based genome file genotypes this structural variant directly, rs1799752 gives the most precise readout of ACE biology.

The I allele (insertion present) results in lower ACE activity; the D allele (deletion) results in higher activity. A substantial fraction of inter-individual variation in serum ACE levels is attributable to this single locus — making it the dominant genetic determinant of RAAS tone across the population.

The Mechanism

The Alu element in intron 16 is not just a neutral marker — it exerts a measurable effect on ACE gene expression at the mRNA level. A direct allele-specific quantification study²² direct allele-specific quantification study
Suehiro T et al. Increased amount of the angiotensin-converting enzyme (ACE) mRNA originating from the ACE allele with deletion. Hum Genet, 2004 in individuals heterozygous for the I/D measured mRNA from each allele separately. The D allele produced, on average, 1.79 times more ACE mRNA than the I allele in the same cell. This is mechanistically distinct from what a nearby tag SNP captures: the Alu element itself influences mRNA stability or splicing efficiency³³ mRNA stability or splicing efficiency
Intronic Alu elements are known to modulate alternative splicing and affect pre-mRNA folding, secondary structure, and interaction with RNA-binding proteins — any of these could reduce I-allele mRNA abundance or stability relative to D-allele mRNA, resulting in a constitutively lower transcriptional output from the I chromosome.

The functional consequence cascades downstream. DD homozygotes carry substantially more serum ACE activity than II homozygotes; ID heterozygotes are intermediate. Higher ACE activity means more angiotensin II⁴⁴ angiotensin II
Angiotensin II is a potent vasoconstrictor and anabolic signalling molecule; it promotes skeletal muscle protein synthesis and cardiac hypertrophy via AT1 receptors, and drives aldosterone secretion, sodium retention, and increased blood pressure and less bradykinin⁵⁵ bradykinin
Bradykinin is a vasodilator that activates nitric oxide synthase, promotes glucose uptake in working muscle via GLUT4 translocation, and improves metabolic efficiency during sustained aerobic effort; it is rapidly degraded by ACE. The II genotype does the reverse: lower ACE, prolonged bradykinin, more efficient aerobic muscle metabolism.

The Evidence

The 2024 updated meta-analysis of rs1799752 and public-health sports modalities — the most comprehensive analysis to date — examined 16 studies through June 2024 and found the II genotype associated with elite endurance athlete status⁶⁶ II genotype associated with elite endurance athlete status
Sommers L et al. Role of the ACE I/D Polymorphism in Selected Public Health-Associated Sporting Modalities: An Updated Systematic Review and Meta-Analysis. Int J Environ Res Public Health, 2024 at OR=1.54 (95% CI 1.24–1.91) versus controls and OR=1.56 (95% CI 1.07–2.28) versus power athletes. Sport-specific analysis revealed the strongest enrichment in triathlon (OR=2.69) and open-water swimming (OR=2.27), with running at OR=1.76.

The mechanistic underpinning for the endurance advantage was clarified by a training study of army recruits⁷⁷ training study of army recruits
Woods DR et al. Endurance enhancement related to the human ACE I-D polymorphism is not due to differences in the cardiorespiratory response to training. Eur J Appl Physiol, 2002 showing that II individuals gained significantly more efficiency — lower oxygen cost at a fixed workload — without a corresponding difference in peak VO2max. The advantage is therefore economic: doing the same aerobic work for less oxygen expenditure, not a larger aerobic ceiling.

For the D allele, evidence converges on strength adaptation and cardiovascular remodelling. DD individuals show larger strength gains per training cycle, greater left ventricular mass increases in response to endurance training, and higher enrichment among sprint and power athletes in multiple cohorts.

The pharmacogenomic dimension of rs1799752 is distinct from its athletic profile. A study of IgA nephropathy patients⁸⁸ study of IgA nephropathy patients
Teranishi J et al. ACE insertion/deletion polymorphism (rs1799752) modifies the renoprotective effect of renin-angiotensin system blockade. J Renin Angiotensin Aldosterone Syst, 2014 found that ACE inhibitors and ARBs significantly slowed disease progression in DD patients but had no measurable renoprotective effect in II patients. This genotype-dependent drug response reflects the underlying biology: DD individuals have more angiotensin II substrate for ACE inhibitors to suppress, whereas II individuals already have low baseline RAAS activity, leaving little room for further reduction.

Practical Implications

• II genotype: Lower ACE activity confers genuine aerobic efficiency advantages, particularly in sustained-output sports (running, triathlon, rowing, altitude events). Training response is likely to favour volume over intensity. ACE inhibitor or ARB therapy, if ever prescribed, may provide less renal protection than it would in DD individuals.
• DD genotype: Higher ACE activity supports strength adaptation and power-based athletics, but also elevates RAAS tone at rest. Cardiovascular monitoring matters regardless of fitness level. If prescribed ACE inhibitors or ARBs (for hypertension, heart failure, or renal protection), the drug acts on a more active target enzyme — these medications tend to be more effective and may produce larger blood pressure reductions.
• ID genotype: Intermediate ACE activity with genuine versatility across athletic modalities. No strong pull toward either endurance or power; training response will be shaped more by program design than genotype.

Relationship to rs4341

rs4341 (the C/G tag SNP, C=insertion, G=deletion) is in near-complete linkage disequilibrium with rs1799752 and can be used as a proxy when direct structural genotyping is unavailable — which is the case for all short-read consumer chip arrays (23andMe v3/v4/v5). When a genome file includes rs1799752 directly (WGS with structural variant calling), this entry provides the definitive interpretation. When only rs4341 is present, the rs4341 entry applies. The underlying biology is identical; the two entries differ only in the confidence of the genotype call and the mechanistic framing.

Interactions

The ACE I/D has been studied alongside ACTN3 R577X (rs1815739)⁹⁹ ACTN3 R577X (rs1815739) in multiple athlete cohorts. The compound combination of ACE II (insertion homozygote) with ACTN3 XX (both alpha-actinin-3 null) appears to compound endurance advantages; ACE DD with ACTN3 RR compounds power and sprint tendencies. These are the best-studied two-locus interactions in exercise genetics — observational, not interventional, but supported by coherent physiological logic.

ACE activity also interacts functionally with AGTR1 A1166C (rs5186)¹⁰¹⁰ AGTR1 A1166C (rs5186) — the angiotensin II type 1 receptor variant. DD individuals who also carry the AGTR1 C allele (more responsive AT1 receptor) may have amplified angiotensin II signalling through both higher ligand production and enhanced receptor sensitivity. This combination may be relevant to cardiovascular risk assessment.

Your immune system deploys chemokine receptors like radio antennas — they pick up distress signals from inflamed tissue and direct immune cells to the scene. CCR5 (C-C chemokine receptor 5)¹¹ CCR5 (C-C chemokine receptor 5)
a G-protein-coupled receptor expressed on T cells, monocytes, and macrophages that binds the chemokines CCL3, CCL4, and CCL5/RANTES, directing immune cell trafficking to sites of infection and inflammation sits at the intersection of infectious immunity and vascular inflammation. The rs1799987 variant, located at position −2459 in the CCR5 promoter, governs how loudly this antenna is tuned — and the consequences ripple from HIV susceptibility to atherosclerotic plaque formation.

Note: This variant is often labeled CCR5 59029 A/G or −2459G>A in the literature. The reference allele on the GRCh38 plus strand is A; the G allele is the alternate.

The Mechanism

The rs1799987 position sits within a regulatory region of the CCR5 promoter that modulates transcriptional output. In vitro reporter assays demonstrate that the G allele reduces CCR5 promoter activity by approximately 45% relative to the A allele²² 45% relative to the A allele
measured in reporter gene assays; Martinson et al. MACS, Lancet 1997. This translates to lower CCR5 mRNA production and fewer CCR5 receptors on the surface of T cells and monocytes. The A allele, by contrast, drives higher CCR5 surface density, expanding both the targets available for CCR5-tropic pathogens and the pool of monocytes equipped to respond to CCL5/RANTES gradients in inflamed vessel walls.

The variant is part of a larger CCR5 haplotype system. The most famous CCR5 variant, CCR5-Δ32 (rs333), is a 32-bp deletion that truncates the receptor; rs1799987 operates through a different mechanism — reduced expression of an otherwise intact receptor.

The Evidence

HIV and immune cell trafficking: The Multicenter AIDS Cohort Study (MACS)³³ Multicenter AIDS Cohort Study (MACS)
Martinson et al. Lancet 1997 established the foundational evidence: in a cohort of HIV-1 seroconverters lacking both CCR5-Δ32 and CCR2-64I alleles, G/G homozygotes progressed to AIDS an average of 3.8 years more slowly than A/A homozygotes (p=0.004). G/G protection was described as approximately twice that of CCR5-Δ32 in this cohort. The mechanism is straightforward: HIV R5-tropic strains use CCR5 as a co-receptor to enter CD4+ T cells; fewer surface receptors means fewer entry points.

Atherosclerosis: CCR5 and its ligands are expressed in human atherosclerotic plaque. CCR5 immunoreactivity is elevated in unstable plaque regions compared to stable regions, colocalizing with smooth muscle cells and macrophages. In ApoE-knockout mice fed a high-fat diet⁴⁴ ApoE-knockout mice fed a high-fat diet
Potteaux et al. Arterioscler Thromb Vasc Biol 2006, genetic deletion of Ccr5 (but not Ccr1) significantly reduced lesion area, macrophage content, and Th1-polarization within plaques, while increasing smooth muscle content and IL-10 expression — a more stable plaque phenotype. Critically, protection was sustained over 22 weeks of high-fat diet, arguing against a transient effect.

Human cardiovascular data are mixed. A Taiwanese case-control study (483 subjects undergoing coronary angiography) found that GG/GA carriers were more frequent among patients with acute coronary syndrome than those with stable CAD or no CAD (OR 1.853, 95% CI 1.176–2.921, p=0.008), though no significant association was seen with stable CAD — an unexpected direction given the HIV biology, possibly reflecting population-specific haplotype context or confounding by CCR5-Δ32 co-distribution. Larger genome-wide studies in European populations have not identified rs1799987 as a significant independent predictor of coronary artery disease, placing the cardiovascular evidence at the emerging-to-moderate level.

Cardiac inflammation: In chronic Chagas disease⁵⁵ chronic Chagas disease
Medeiros et al. PLOS One 2015, the AA genotype was significantly more common in patients with the cardiac form than in those with digestive-form disease or healthy controls (recessive model, p=0.036), fitting the model that higher CCR5 expression on leukocytes drives the intense myocarditis characteristic of cardiac Chagas disease.

Inflammatory disease: In Löfgren's syndrome (sarcoidosis)⁶⁶ Löfgren's syndrome (sarcoidosis)
Loke et al. Cells 2021 (106 patients, 257 controls), the G allele was more frequent in patients (OR 1.680, p=0.0015), while GG carriers showed higher CCR5 surface density on monocytes but paradoxically impaired downstream calcium signaling — suggesting that genotype-driven expression differences and functional receptor coupling are dissociable.

Practical Actions

The cardiovascular implications of rs1799987 are at the level of monocyte-driven plaque inflammation rather than a single binary risk. AA homozygotes carry the highest CCR5-driven inflammatory burden at the vascular wall, supporting stricter attention to cardiovascular risk factors that interact with the CCR5/CCL5 axis — notably obesity, smoking, and chronic infection, each of which elevates circulating CCL5/RANTES. AG heterozygotes occupy an intermediate position.

For individuals with concurrent cardiovascular risk, the CCR5 promoter genotype provides biological context: the A allele predicts a monocyte population primed for CCL5-driven tissue recruitment. This makes anti-inflammatory lifestyle measures particularly mechanistically relevant, and surveillance for subclinical atherosclerosis (carotid intima-media thickness, coronary calcium scoring) a targeted investment.

Interactions

The rs1799987 A allele acts in the same inflammatory recruitment pathway as the CCL2 promoter variant rs1024611 (MCP-1 A-2518G, also in heart-inflammation). Both variants raise the set-point of monocyte recruitment to inflamed tissue — rs1024611 via more MCP-1 ligand; rs1799987 via more CCR5 receptor. Individuals carrying risk alleles at both loci may experience amplified monocyte trafficking to atherosclerotic plaques, though no direct compound study has been published for this specific combination.

CCR5-Δ32 (rs333), the 32-bp deletion that eliminates surface CCR5 expression almost entirely, is a distinct and stronger variant: Δ32 homozygotes lack functional CCR5 and are virtually immune to CCR5-tropic HIV. Heterozygous Δ32 carriers have approximately 50% fewer surface receptors than wild-type. The rs1799987 G allele operates through the same direction (reduced expression) but with a more modest ~45% reduction in transcription versus Δ32's near-complete loss of function.

The insulin/IGF-1 signaling (IIS) pathway is the most conserved longevity pathway across all studied species. Reduce it in yeast, worms, flies, or mice, and lifespan extends. IRS2 — insulin receptor substrate 2 — is the critical intracellular docking protein that receives the IGF-1 receptor's signal and amplifies it through the PI3K-AKT-mTOR cascade. In mice, complete IRS2 knockout extends median lifespan by up to 20%¹¹ In mice, complete IRS2 knockout extends median lifespan by up to 20%
White MF. IRS2 integrates insulin/IGF1 signalling with metabolism, neurodegeneration and longevity. Diabetes Obes Metab. 2014. rs1805097 creates a glycine-to-aspartic acid substitution at position 1057 of the IRS2 protein — a structural shift in the C-terminal domain that alters the protein's signaling efficiency. Homozygous carriers of the Asp variant are approximately twice as likely to reach extreme old age.

The Mechanism

IRS2 sits just downstream of both the insulin receptor and the IGF-1 receptor (IGF1R). When either receptor is activated, IRS2 becomes tyrosine-phosphorylated and recruits PI3-kinase, triggering a cascade culminating in AKT and mTOR activation. This drives growth, protein synthesis, and cellular proliferation — metabolically costly processes that appear to accelerate biological aging²² accelerate biological aging
White MF. 2014.

The Gly1057Asp substitution falls within the C-terminal serine phosphorylation domain of IRS2. Position 1057 lies near a cluster of regulatory serine residues that govern IRS2 stability and interaction with downstream signaling partners. The aspartic acid substitution (negatively charged, versus neutral glycine) may subtly alter the protein's folding and its interaction with 14-3-3 proteins and E3 ubiquitin ligases — mechanisms that control IRS2 protein levels. The result appears to be modestly attenuated IIS flux, which the longevity literature uniformly associates with extended healthspan. Importantly, the fasting C-peptide levels of Asp allele carriers are inversely correlated with allele dosage in lean individuals, suggesting higher insulin sensitivity — a fundamentally different mechanism than the lifespan extension observed in IRS2 knockout mice, and one that is highly context-dependent.

The Evidence

The primary human longevity study comes from Barbieri et al. 2010³³ Barbieri et al. 2010
Barbieri M et al. The IRS2 Gly1057Asp variant is associated with human longevity. J Gerontol A Biol Sci Med Sci. 2010. Among 677 Italian participants (ages 16-104), homozygous Asp/Asp individuals were significantly overrepresented among long-lived subjects (>85 years old) compared to controls (16.7% vs 12.0%, p = .04). When focused on extreme old age (ages 96-104), Asp/Asp individuals had a 2.03-fold increased probability of reaching that age (95% CI 1.39-2.99, p = .0003). After adjusting for anthropometric and metabolic covariates, the overall longevity odds ratio was 2.07 (95% CI 1.38-3.12, p = .001), confirming the association is independent of body weight and metabolic status.

A gene-combination study Barbieri et al. 2012⁴⁴ Barbieri et al. 2012
Barbieri M et al. A/Asp/Val allele combination of IGF1R, IRS2, and UCP2 genes is associated with better metabolic profile, preserved energy expenditure parameters, and low mortality rate in longevity. Age (Dordr). 2012 examined 722 Italian subjects and found that when the IRS2-Asp allele is combined with the IGF1R longevity A-allele (rs2229765) and the UCP2 Val allele (rs659366), the longevity association is dramatically amplified: OR 3.185 (95% CI 1.63-6.19, p = .0006). The combination also correlated with lower HOMA-IR (diff −0.532, p = 0.003), higher resting metabolic rate (diff ~102 kcal/day, p = 0.038), and decreased all-cause mortality (HR 0.72) over six years of follow-up.

The critical contextual finding comes from Mammarella et al. 2000⁵⁵ Mammarella et al. 2000
Mammarella S et al. Interaction between the G1057D variant of IRS-2 and overweight in the pathogenesis of type 2 diabetes. Hum Mol Genet. 2000. In Italian subjects without overweight, the Asp allele dose-dependently protected against type 2 diabetes (DD genotype OR 0.18, 95% CI 0.04-0.68; p for trend = .0012). But in overweight subjects, the same genotype reversed to dramatically increase diabetes risk (DD OR 5.74, 95% CI 1.11-29.78; p for trend = .0047). This genotype-environment interaction is one of the most dramatic in the IIS literature and fundamentally shapes how to interpret your results.

Practical Implications

The Asp variant's longevity benefit appears to operate through subtly reduced IIS flux in the lean state, where higher insulin sensitivity reduces the chronic mTOR activation that accelerates cellular aging. Maintaining normal body weight is therefore the primary intervention for Asp allele carriers — not because weight management is generic health advice, but because this specific variant's protective effect mechanistically depends on metabolic context. Overweight Asp/Asp carriers face a compound risk: their attenuated IRS2 signaling, combined with the chronic hyperinsulinemia of obesity, creates insulin resistance rather than insulin sensitivity.

Monitoring fasting insulin and HOMA-IR (calculated from fasting glucose and insulin) provides a direct readout of whether your IRS2 variant is functioning in its protective mode or reverting to its insulin-resistant mode. Asp/Asp individuals in their 60s and beyond should also monitor for signs of cardiac metabolic risk, as one study found higher epicardial fat thickness in elderly Asp carriers, independent of body weight.

Interactions

The strongest documented interaction is the IGF1R-IRS2-UCP2 triple combination. IGF1R rs2229765 sits directly upstream of IRS2 in the signaling cascade; when both genes carry their longevity variants, the combined attenuation of IIS flux is amplified beyond either variant alone. UCP2 rs659366 (Val allele) modulates mitochondrial uncoupling downstream of the pathway, adding a third layer of IIS attenuation. The OR of 3.185 for the triple combination versus ~2.0 for IRS2 alone quantifies this synergy.

The IIS pathway also intersects with neurodegeneration: reduced IRS2 signaling protects against tau hyperphosphorylation and amyloid accumulation in animal models of Alzheimer's disease. Human brains with Alzheimer's disease show specifically reduced IRS2 levels in affected neurons. Whether the Gly1057Asp variant modifies dementia risk in humans has not been directly tested.

Every pancreatic beta cell contains a molecular glucose sensor — the enzyme glucokinase¹¹ glucokinase
GCK (hexokinase-4): the first enzyme to phosphorylate glucose in beta cells, setting the threshold at which insulin secretion begins. Normal GCK triggers insulin release when blood glucose rises above ~5 mmol/L. This variant, GCK p.Phe316Tyr (rs193922339), substitutes phenylalanine with tyrosine at position 316 in the large catalytic subdomain of the protein. The result is reduced glucokinase activity — and a glucose "thermostat" that is chronically set several points too high, producing lifelong mild fasting hyperglycemia that is almost always asymptomatic.

This is MODY2²² MODY2
Maturity-Onset Diabetes of the Young type 2, also called GCK-MODY: the most common form of monogenic diabetes, caused by heterozygous loss-of-function variants in the GCK gene. Unlike type 1 or type 2 diabetes, MODY2 is stable, non-progressive, and rarely requires medication, not the slowly progressive metabolic failure of type 2 diabetes.

The Mechanism

Glucokinase is the rate-limiting glucose sensor in pancreatic beta cells. Wild-type GCK has a sigmoidal glucose–response curve with a half-saturation glucose concentration (S0.5) near 8 mM — it effectively becomes active only when postprandial glucose rises into that range, triggering the insulin surge that keeps blood sugar in the normal range. In heterozygous GCK-MODY carriers, only one functional copy of GCK is present. The mutant p.Phe316Tyr protein resides in the large subdomain at a structural helix-turn element (residues 316-318) that contributes to the enzyme's conformational dynamics. With 50% of normal GCK activity, the beta cell's effective glucose threshold shifts upward by approximately 1.5–2.5 mmol/L. The body reaches a new, stable setpoint — fasting glucose typically ranging 5.4–8.0 mmol/L³³ fasting glucose typically ranging 5.4–8.0 mmol/L
97–144 mg/dL in most carriers, with HbA1c 5.6–7.6% — and holds there for life.

The Evidence

Carmody et al. 2016⁴⁴ Carmody et al. 2016
GCK-MODY in the US National Monogenic Diabetes Registry: Frequently Misdiagnosed and Unnecessarily Treated. Acta Diabetol, 2016 analysed 120 GCK-MODY patients: median pre-diagnosis HbA1c was 6.4%, and almost half (49%) had been given glucose-lowering medications unnecessarily. After genetic confirmation, 79.2% safely discontinued treatment with no change in glycaemic control — confirming the condition's pharmacological non-responsiveness.

Kleinberger & Pollin 2015⁵⁵ Kleinberger & Pollin 2015
Undiagnosed MODY: Time for Action. Curr Diab Rep estimated that ~95% of MODY cases in the USA remain undiagnosed, with most GCK-MODY patients incorrectly labelled as type 2 or type 1 diabetic. GCK-MODY carriers do not develop the typical complications of diabetes because hyperglycemia does not worsen beyond the new setpoint.

Galán et al. 2005⁶⁶ Galán et al. 2005
Biochem J functionally characterised multiple novel GCK MODY missense variants, finding that all patients presented with mild fasting hyperglycemia (6.6–8.0 mM), responded well to dietary management, and showed no progression to diabetic complications over follow-up — consistent with the broadly benign prognosis of single-copy GCK loss.

In pregnancy, Timsit et al. 2022⁷⁷ Timsit et al. 2022
Front Endocrinol showed that maternal GCK-MODY affects fetal growth differently depending on whether the fetus inherited the variant. Non-carrying fetuses face 33–65% macrosomia rates compared with only 4–13% in fetuses that inherited the mutation. Crucially, the fetal genotype — not maternal insulin treatment — was the primary driver of macrosomia risk.

Practical Actions

The key insight from genetic diagnosis is what to stop rather than start. If previously labelled as type 2 diabetic and started on metformin or other agents, most GCK-MODY patients can safely discontinue medication under physician supervision without any worsening of glycaemia. Fasting glucose levels need to be monitored but not aggressively treated.

Dietary management focuses on reducing postprandial glucose spikes rather than aiming for normoglycaemia — pushing glucose below the carrier's natural setpoint with aggressive therapy often causes hypoglycemia without benefit.

Pregnancy is the most important management exception. Serial ultrasound monitoring of fetal abdominal circumference from 26 weeks is recommended, and insulin therapy is only initiated when fetal growth exceeds the 75th percentile. Non-invasive fetal genotyping, where available, can personalise this decision further by identifying which fetuses actually need monitoring for macrosomia.

Interactions

GCK-MODY caused by heterozygous variants behaves as autosomal dominant with full penetrance — nearly all heterozygous carriers have the raised glucose setpoint. The condition does not interact in a meaningful additive way with common type 2 diabetes polygenic risk, because the mechanism is entirely distinct (glucose sensing threshold vs insulin resistance). Homozygous or compound heterozygous GCK variants (two loss-of-function alleles) cause permanent neonatal diabetes mellitus (PNDM), a far more severe neonatal condition requiring insulin from birth — but this is an entirely different clinical entity.

Cardiac alpha-actin is the molecular backbone of every heartbeat. Encoded by the ACTC1 gene, it polymerizes into thin filaments that interdigitate with myosin heavy chains to generate the force your heart needs to eject blood. The p.Glu101Lys variant — a single amino acid substitution at position 101 of this actin — disrupts the mechanical handshake between actin and myosin in a way that forces the heart to compensate, sometimes silently for decades.

This is a rare but high-impact pathogenic variant. ClinVar classifies it as Pathogenic with 4-star expert panel review¹¹ 4-star expert panel review
ClinGen Cardiomyopathy Variant Curation Expert Panel, November 2025, the highest confidence level ClinVar assigns.

The Mechanism

Glutamic acid at position 101²² Glutamic acid at position 101
a negatively charged amino acid in subdomain 1 of actin sits directly adjacent to the myosin head binding interface. Substituting the negatively charged glutamate with the positively charged lysine (E101K) disrupts this electrostatic environment and reduces myosin binding affinity. In vitro studies show the mutation produces slower actin-myosin sliding velocity, reduced force generation, and a weaker actomyosin interaction in the presence of ATP.

The net effect is a compensatory increase in myofibrillar calcium sensitivity — the heart tries to squeeze more contractile force from each calcium transient. This hypersensitivity to calcium is mechanistically linked to the resulting hypertrophy, particularly concentrated at the cardiac apex³³ cardiac apex
the pointed tip of the left ventricle, frequently the last region affected in typical HCM. A transgenic mouse model expressing the closely related E99K mutation reproduced apical hypertrophy with increased interstitial fibrosis and sarcomere disarray, and showed a 2.3-fold increase in calcium sensitivity in reconstituted thin filaments.

The Evidence

The landmark family study by Monserrat et al. (2007)⁴⁴ Monserrat et al. (2007)
Mutation in the alpha-cardiac actin gene associated with apical HCM, LVNC, and septal defects. Eur Heart J, 2007 screened 247 HCM/LVNC families and found ACTC1 E101K in 5 probands. Among 46 mutation-positive family members, 22 met criteria for apical hypertrophic cardiomyopathy, 23 fulfilled criteria for left ventricular noncompaction (LVNC), and 9 had atrial or ventricular septal defects. Five premature sudden cardiac deaths and one heart transplant were documented among carriers.

Arad et al. (2005)⁵⁵ Arad et al. (2005)
Gene mutations in apical hypertrophic cardiomyopathy. Circulation, 2005 identified E101K in two families and noted that all 16 affected members showed exclusively apical hypertrophy — a remarkably consistent phenotype rarely seen with other sarcomere gene mutations.

The 2024 AHA/ACC HCM guideline ⁶⁶ Ommen et al. Circulation, 2024 endorses ACTC1 as a definitive HCM gene requiring cascade screening, periodic echocardiographic surveillance, and risk stratification for sudden cardiac death in gene-positive individuals.

A 2025 case series ⁷⁷ Zarate et al. Clin Genet, 2025 expanded the phenotypic spectrum further, noting that ACTC1 Glu101 variants can present with extracardiac features including facial dysmorphism and skeletal anomalies in some kindreds, widening the clinical picture beyond isolated cardiomyopathy.

Practical Actions

Carriers of the T allele require structured cardiac surveillance regardless of symptoms. Apical HCM is frequently missed on standard echocardiography if the apex is not specifically evaluated; contrast echocardiography or cardiac MRI can improve detection. LVNC overlap phenotypes require attention to trabeculation depth and left ventricular systolic function.

The 2024 AHA/ACC guidelines recommend echocardiography every 1-2 years for gene-positive children and every 3-5 years for asymptomatic gene-positive adults. Cardiology review should be prompted immediately if symptoms develop (palpitations, exertional dyspnoea, syncope, chest pain) or if echocardiographic surveillance shows new wall thickening, systolic dysfunction, or increased LV trabeculation.

Sudden cardiac death risk stratification (using the HCM Risk-SCD calculator or equivalent) should be performed by a cardiologist with HCM expertise; ICD implantation may be recommended for carriers with additional risk features (maximum wall thickness ≥30 mm, non-sustained VT, unexplained syncope, family history of SCD, or abnormal blood pressure response to exercise).

Cascade genetic testing of first-degree relatives (parents, siblings, children) should be offered. Each first-degree relative has a 50% probability of inheriting the variant. Variant-negative relatives can be discharged from cardiac surveillance; variant-positive relatives enter the surveillance programme regardless of echocardiographic findings at baseline.

Interactions

ACTC1 E101K acts through the sarcomere, the same final effector pathway as MYH7, MYBPC3, TNNT2, TNNI3, TPM1, and MYL2 mutations. Individuals who carry two sarcomere gene mutations (digenic disease) generally present with earlier onset and more severe phenotypes. If a variant is found in ACTC1, genetic panels should evaluate for concurrent mutations in other sarcomere genes. Compound sarcomere mutation carriers warrant accelerated surveillance and lower thresholds for ICD consideration. No specific ACTC1 E101K gene-drug interactions affecting cardiac drug efficacy have been identified.

Most genetic research on nicotine dependence has focused on a single amino acid change in the CHRNA5 gene (rs16969968, D398N), but the 15q25.1 locus harbors a second distinct mechanism: a cis-regulatory variant that controls how much CHRNA3 and CHRNA5 are made in the first place. rs2036527 sits approximately 511 base pairs upstream of CHRNA5¹¹ rs2036527 sits approximately 511 base pairs upstream of CHRNA5
Located in an intergenic enhancer between PSMA4 and CHRNA5, this variant was long assumed to be a proxy for rs16969968 but recent functional work shows it acts independently in a regulatory element that loops to the CHRNA3 promoter and simultaneously influences CHRNA5 expression. The A allele is the risk form — it reduces enhancer activity and perturbs the output of both nicotinic receptor genes in concert.

rs2036527 is especially important for people of African ancestry. In Europeans the closely related coding variant rs16969968 is common (~35% minor allele frequency) and dominates association signals; in African Americans rs16969968 is nearly absent, yet 15q25.1 still strongly predicts smoking behavior. The African ancestry GWAS meta-analysis spanning 32,389 individuals²² The African ancestry GWAS meta-analysis spanning 32,389 individuals
Study of Tobacco in Minority Populations Genetics Consortium across 13 cohorts found rs2036527 to be the top genome-wide significant hit for cigarettes per day in this population (P=1.84×10⁻⁸), meaning it captures an independent regulatory signal that the rs16969968-centred haplotype misses entirely in non-European cohorts.

The Mechanism

The CHRNA5 gene and the adjacent CHRNA3 gene encode the α5 and α3 subunits of the nicotinic acetylcholine receptor (nAChR), the brain's principal sensor for nicotine. rs2036527 lies within a chromatin domain that physically loops to contact the CHRNA3 promoter — a long-range regulatory interaction confirmed by 3C (chromosome conformation capture) assay³³ 3C (chromosome conformation capture) assay
3C quantifies how often two genomic segments touch, which indicates functional regulatory contact. The risk-A allele alters the binding site for the transcription factor FOXA2 (forkhead box A2)⁴⁴ FOXA2 (forkhead box A2)
FOXA2 is a pioneer transcription factor that opens chromatin and recruits other activators, reducing enhancer activity as demonstrated by luciferase reporter assay. Because the same enhancer loops to both CHRNA3 and CHRNA5, impaired FOXA2 binding suppresses expression of both receptor subunits simultaneously.

This regulatory mechanism is distinct from, and partially independent of, the D398N amino acid variant in rs16969968. In Europeans the two signals are in high LD (r²≈0.93), making it difficult to separate their contributions. In African Americans, where rs16969968 is nearly monomorphic (minor allele frequency ~2%), rs2036527 acts as the sole carrier of genetic risk at this locus — demonstrating its independent causal role.

The Evidence

The regulatory function of rs2036527 was established by Peng et al. 2025⁵⁵ Peng et al. 2025
Peng et al. Identification of rs2036527 as a cis-regulatory variant for CHRNA3 and CHRNA5. Am J Addictions, 2025, who combined allele-specific expression analysis, chromatin conformation capture, luciferase assay, and expression quantitative trait locus (eQTL) validation to pin the mechanistic responsibility on rs2036527 rather than on surrounding proxy variants.

For smoking behavior, the STOMP Genetics Consortium meta-analysis⁶⁶ STOMP Genetics Consortium meta-analysis
Study of Tobacco in Minority Populations Genetics Consortium, pooling data from 13 studies found that each copy of the A allele increases cigarettes smoked per day by approximately one cigarette (β=0.040 in log-CPD units). Mean daily consumption by genotype was 14.6 cigarettes for AA, 13.5 for AG, and 12.8 for GG, demonstrating a clean additive gradient.

For lung cancer, a GWAS in 4,702 African American cases and controls⁷⁷ GWAS in 4,702 African American cases and controls
Confirmed 15q25.1 as a lung cancer locus in this population found rs2036527 associated with risk (OR=1.32, 95% CI 1.20–1.44, P=1.3×10⁻⁹). An earlier case-control study reported OR=1.67 (95% CI 1.26–2.21) in African Americans, and even among never-smokers rs2036527 remained associated with lung cancer risk (OR=1.58, 95% CI 1.12–2.26, P=9.9×10⁻³), suggesting both behavioral and potentially direct tissue effects.

Cessation pharmacotherapy outcomes also vary by genotype. A pharmacogenomics study in 1,295 African-American smokers randomized to nicotine gum or bupropion⁸⁸ 1,295 African-American smokers randomized to nicotine gum or bupropion
Randomized clinical trial design; one of the few cessation pharmacogenomics studies in an African American population found that A allele carriers had substantially lower abstinence rates with active pharmacotherapy during treatment (OR=0.42, P<0.001) and at end of treatment (OR=0.55, P=0.004). The effect was most pronounced for nicotine gum (OR=0.31, P<0.001 during treatment). Interestingly, a complementary study found that in women, the GA and AA genotypes were associated with higher cessation success rates⁹⁹ higher cessation success rates
41.5% and 56.5% for GA and AA vs 34.8% for GG in women, suggesting sex and treatment context modulate the genotype effect.

Practical Actions

The A allele weakens expression of nicotinic receptor subunits, blunting the normal aversive response to high nicotine doses that acts as a brake on heavy smoking. The consequence is the same as for rs16969968 carriers — easier escalation to heavy smoking, harder cessation — but the molecular route is different (gene expression rather than receptor function). In non-European populations where rs16969968 is rare, rs2036527 provides the actionable genetic signal.

Awareness of the genotype is most useful for (a) pre-smoking risk counseling, (b) selecting cessation pharmacotherapy, and (c) lung cancer surveillance planning. Nicotine replacement monotherapy appears less effective for A allele carriers; agents acting on nAChRs by a different route — specifically varenicline — are preferable. Lung cancer screening discussions should incorporate this variant, especially in individuals with any smoking history.

Interactions

In European populations, rs2036527 is in substantial LD (r²≈0.93) with the nonsynonymous CHRNA5 variant rs16969968 and near-complete LD with the CHRNA3 synonymous variant rs1051730, meaning all three variants are usually inherited together. A person whose genome includes both rs16969968(A) and rs2036527(A) carries a compounded mechanism: impaired receptor function (D398N structural change) plus reduced receptor gene expression (enhancer disruption). In African and other non-European populations, the LD breaks down (r²=0.44–0.50 with rs1051730 in African ancestry; rs16969968 nearly absent), making rs2036527 the primary causal variant — and the only variant providing meaningful genetic risk information at this locus for most people outside European ancestry.

The 15q25.1 locus has also been associated with risk for schizophrenia and bipolar disorder through variants in strong LD with rs1051730, suggesting that nicotinic receptor expression regulated by this enhancer cluster may influence broader neuropsychiatric vulnerability beyond tobacco dependence.

Inside the nucleus and cytoplasm of every cell, molecular motors called kinesins ferry cargo along microtubule tracks. KIF6 (kinesin family member 6) is one of these motors, and while its precise cellular role is still being worked out, it has attracted intense scrutiny for one reason: a common amino acid variant at position 719 — swapping tryptophan for arginine — appeared in large prospective trials to dramatically reshape who benefits from statin therapy.

The Mechanism

The Trp719Arg substitution (plus-strand G allele at chr6:39357302) changes an uncharged, bulky amino acid (tryptophan) to a positively charged one (arginine) in the tail domain of the KIF6 motor protein. KIF6 is expressed in cardiomyocytes, smooth muscle cells, and cilia, where it is thought to regulate cytoskeletal dynamics and intracellular vesicle transport. The exact mechanism connecting the 719Arg variant to cardiovascular risk and statin sensitivity remains incompletely characterized — the statin interaction notably occurs independently of LDL cholesterol lowering¹¹ occurs independently of LDL cholesterol lowering
the benefit was observed without differences in LDL or CRP between groups, suggesting a non-lipid pathway, pointing toward a direct effect on cell signaling or endothelial biology.

The Evidence

The KIF6 story has two chapters: an exciting initial phase and a sobering replication phase.

Chapter 1 — The original trials. In 2008, Iakoubova et al. published a cluster of studies from four major randomized controlled trials. In the CARE and WOSCOPS trials²² CARE and WOSCOPS trials, 719Arg carriers on placebo had a 50–55% higher risk of coronary events than non-carriers (CARE HR 1.50, 95% CI 1.05–2.15; WOSCOPS OR 1.55, 95% CI 1.14–2.09). Pravastatin reduced their absolute risk by 4.89% (CARE) and 5.49% (WOSCOPS) — while providing near-zero benefit in non-carriers. The PROVE IT-TIMI 22 trial³³ PROVE IT-TIMI 22 trial in acute coronary syndrome patients showed that intensive statin therapy halved event rates in 719Arg carriers (HR 0.59) but had no significant effect in non-carriers (HR 0.94), with an interaction p = 0.018 and a 10% vs. 0.8% absolute risk reduction. The PROSPER trial⁴⁴ PROSPER trial in elderly patients confirmed the pattern: in carriers with prior vascular disease, pravastatin HR was 0.66 vs. 0.94 in non-carriers. A meta-review of all four trials⁵⁵ meta-review of all four trials yielded number-needed-to-treat of 10–20 for 719Arg carriers versus over 80 for non-carriers — a striking pharmacogenomic signal.

Chapter 2 — The replication crisis. In 2010, Assimes et al. published a definitive replication attempt⁶⁶ definitive replication attempt in 19 independent case-control studies comprising 17,000 cases and 39,369 controls across multiple ancestries. None of the 19 studies showed increased CAD risk in 719Arg carriers; the meta-analysis ruled out with high confidence even a 2% risk increase in Europeans. A 2018 pooled analysis⁷⁷ pooled analysis of 50 studies (40,059 cases, 64,032 controls) confirmed: OR 1.007 under the homozygote model, p = 0.801 — no CAD association. The original risk signal⁸⁸ original risk signal appears to have been a survival bias artefact specific to the prospective cohort design.

The current position. The CAD risk association from Chapter 1 is not supported by the larger replication literature. The pharmacogenomic statin-response signal is more robust — it has been replicated in multiple trials under consistent analytical frameworks — though it also has not been incorporated into CPIC or DPWG clinical guidelines and the mechanistic explanation is incomplete.

Practical Actions

The ~59% of people who carry at least one G (Arg) allele have moderate-strength evidence that they will derive greater-than-average benefit from statin therapy if they develop cardiovascular risk factors. Non-carriers have multiple large trials suggesting pravastatin and possibly other statins may offer them materially less benefit per unit of drug. This genotype does not determine whether to start a statin — that decision depends on absolute cardiovascular risk — but it can inform the relative priority of statin initiation when the clinical picture is borderline, and it may support discussion of statin choice and dose intensity with a cardiologist.

Interactions

KIF6 rs20455 was one of five variants in a composite CHD genetic risk score (ARIC cohort, Bare 2007, PMID 18073581)⁹⁹ composite CHD genetic risk score (ARIC cohort, Bare 2007, PMID 18073581) alongside rs2298566 (SNX19), rs3900940 (MYH15), rs7439293 (PALLD), and rs1010 (VAMP8). Those with a high score across all five variants had HR 1.57 for incident CHD over 13 years. The combined score performed better than any individual variant alone, suggesting these variants capture partially independent biological pathways. Within the KIF6 locus, rs20455 is in high linkage disequilibrium (r² > 0.84) with rs9462535 and rs9471077, which show the same statin-differential pattern.

Every bacterium carries muramyl dipeptide (MDP) in its cell wall — a molecular signature that the NOD2 protein uses as an early warning alarm inside intestinal cells. When bacteria breach the gut epithelium, NOD2 binds MDP¹¹ NOD2 binds MDP
NOD2 directly binds MDP via its leucine-rich repeat domain, triggering downstream NF-κB activation and antimicrobial defense and triggers a tightly controlled inflammatory response. The 3020insC variant (also written c.3019dup or L1007fsX1008) inserts a single cytosine into a run of C's in exon 11, shifting the reading frame and producing a truncated protein lacking the last 33 amino acids²² truncated protein lacking the last 33 amino acids
the truncation removes the terminal 10th leucine-rich repeat, the domain that directly contacts MDP. The result is a protein that can no longer sense bacteria — leaving the gut immune system functionally blind to microbial invasion.

The 3020insC frameshift was independently discovered in 2001³³ independently discovered in 2001
Ogura et al. and Hugot et al. simultaneously identified NOD2 variants, including 3020insC, as the first specific genetic risk factors for Crohn's disease by two groups simultaneously and remains the single most important Crohn's disease susceptibility variant in people of European descent. It is virtually absent in Asian populations, which helps explain why Crohn's disease has different genetic architecture in East Asian compared to European patients.

The Mechanism

The frameshift shifts the translation reading frame starting at codon 1007, replacing leucine with proline and introducing a stop codon two residues later (Leu1007ProfsX1008). The resulting truncated protein lacks the 10th leucine-rich repeat⁴⁴ 10th leucine-rich repeat
the NOD2 LRR domain forms a horseshoe-shaped structure; the 10th repeat is critical for MDP binding, which is required for MDP recognition and NF-κB activation. This is a complete loss-of-function mutation⁵⁵ loss-of-function mutation
unlike R702W and G908R, which cause partial impairment, the frameshift abolishes MDP sensing entirely at physiological concentrations.

Ordinarily, NOD2 in ileal Paneth cells coordinates two protective functions: it activates NF-κB to initiate bacterial defense, and it downregulates excessive Toll-like receptor (TLR) signaling⁶⁶ downregulates excessive Toll-like receptor (TLR) signaling
NOD2-mediated MDP recognition normally dampens TLR4 responses to prevent inflammatory overactivation from commensal bacteria. The 3020insC mutation eliminates both functions simultaneously. Without proper MDP sensing, Paneth cells produce fewer cryptdins (defensins)⁷⁷ cryptdins (defensins)
antimicrobial peptides secreted by Paneth cells to control the bacterial load in the terminal ileum, TLR responses are dysregulated, and the gut becomes susceptible to inappropriate inflammatory responses against commensal bacteria — the hallmark of Crohn's disease.

The Evidence

The original 2001 discoveries were rapidly confirmed worldwide. A meta-analysis of 75 case-control studies⁸⁸ meta-analysis of 75 case-control studies
18,727 Crohn's disease cases and 17,102 controls across multiple populations established the effect sizes with precision: heterozygous carriers (DI genotype) have an odds ratio of 3.8 (95% CI 3.4–4.3) for Crohn's disease, and homozygous or compound heterozygous carriers face an OR of approximately 34 — a risk elevation unmatched by virtually any other common complex disease variant.

The genotype-phenotype correlation is equally striking. Among 1,066 Crohn's disease patients, rs2066847 allele frequency was 15.6% in patients with aggressive disease versus 8.2% in patients with mild disease⁹⁹ Among 1,066 Crohn's disease patients, rs2066847 allele frequency was 15.6% in patients with aggressive disease versus 8.2% in patients with mild disease
p.Leu1007fsX1008 is a strong predictor of aggressive vs mild disease course. A study of all 54 homozygous carriers showed a uniformly aggressive phenotype¹⁰¹⁰ uniformly aggressive phenotype
all homozygotes who were active smokers developed ileal stenosis requiring surgery: 87% had ileal stenosis, 68.5% had fistulas, and 72.2% required Crohn's-related surgery despite immunosuppressive therapy in 87% of cases. Among homozygotes who were active smokers, every single patient required surgery.

Critically, the mutation's association is highly specific to Crohn's disease¹¹¹¹ highly specific to Crohn's disease
no significant association with ulcerative colitis, other IBD forms, or most other inflammatory conditions. The variant is also essentially absent in Asian populations, consistent with the known epidemiological differences in Crohn's disease incidence and genetics between European and non-European populations.

Practical Implications

Most 3020insC heterozygous carriers (DI genotype) never develop Crohn's disease — penetrance is incomplete and requires additional genetic and environmental triggers. However, if symptoms of intestinal inflammation develop, the genotype argues for prompt, thorough evaluation with a gastroenterologist. Fecal calprotectin is a sensitive, non-invasive marker of intestinal inflammation that can be used for routine monitoring in carriers.

For homozygous or compound heterozygous carriers (those who also carry R702W [rs2066844] or G908R [rs2066845] on the other chromosome), the clinical picture is fundamentally different: if Crohn's disease develops, it is expected to be ileal, stricturing, and medically refractory. A "top-down" approach — early initiation of biologic therapy rather than step-up from aminosalicylates — is supported by the literature for these patients. Smoking cessation is particularly urgent, as the smoking-NOD2 interaction is specific to the 1007fs mutation and results in universally aggressive outcomes in homozygotes.

Interactions

The 3020insC variant is the most severe of the three major NOD2 mutations. Compound heterozygotes — individuals carrying 3020insC on one chromosome and either R702W (rs2066844) or G908R (rs2066845) on the other — face risk equivalent to homozygotes for 3020insC, with an OR of ~34 and 98% specificity for complicated stricturing disease¹²¹² OR of ~34 and 98% specificity for complicated stricturing disease
compound heterozygotes and homozygotes have equivalent risk; both dramatically exceed simple heterozygotes.

NOD2 also recruits ATG16L1 (rs2241880)¹³¹³ ATG16L1 (rs2241880)
ATG16L1 is essential for autophagy of intracellular bacteria; NOD2 directly recruits the ATG16L1 complex to bacterial entry sites to bacterial entry sites in the gut epithelium. When both NOD2 function is abolished (3020insC) and ATG16L1 autophagy is impaired (T300A variant), intracellular bacterial clearance fails through two convergent mechanisms, amplifying Crohn's risk. Similarly, IL23R variants (rs11209026) that increase Th17 inflammatory responses compound NOD2 loss-of-function by driving the adaptive immune arm of intestinal inflammation.

MAP2K5 (Mitogen-Activated Protein Kinase Kinase 5, also known as MEK5) encodes a critical signaling kinase in the MAPK signaling cascade¹¹ MAPK signaling cascade
A chain of proteins that relays signals from cell surface receptors to the nucleus, controlling cell growth, differentiation, and survival. MEK5 is the sole known activator of ERK5²² ERK5
Extracellular signal-regulated kinase 5, the terminal kinase in this pathway that directly controls gene expression programs for adipocyte differentiation, making this pathway a key gatekeeper of fat cell formation.

The rs2241423 variant sits within the last intron of MAP2K5 on chromosome 15 and was identified in one of the largest BMI GWAS meta-analyses ever conducted.

The Mechanism

The MEK5-ERK5 pathway acts as a brake on adipogenesis³³ adipogenesis
The process by which precursor cells differentiate into mature fat-storing adipocytes. When MEK5 is active, it phosphorylates ERK5, which in turn suppresses the adipogenic transcription program via the PKA signaling axis⁴⁴ PKA signaling axis
Protein kinase A pathway, which interacts with ERK5 to modulate the balance between fat cell formation and maintenance of the precursor state.

Fine-mapping studies have identified rs7175517 (in near-perfect linkage disequilibrium with rs2241423, r² = 0.99) as the likely causal variant⁵⁵ causal variant
Lu et al. showed through dual-luciferase assays and electrophoretic mobility shift assays that the G allele at rs7175517 binds more RNA splicing regulators, reducing MAP2K5 mRNA expression. The G allele binds more spliceosomes, reducing MAP2K5 expression. Less MEK5 protein means less ERK5 activation, which releases the brake on adipogenesis — resulting in more fat cell formation.

Additionally, miR-143⁶⁶ miR-143
A microRNA that independently suppresses MAP2K5 expression targets MAP2K5 mRNA to promote adipocyte differentiation, establishing the MEK5-ERK5 axis as a convergent regulatory node for fat cell biology.

The Evidence

The Speliotes et al. 2010 GWAS⁷⁷ Speliotes et al. 2010 GWAS
Speliotes et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet, 2010 identified the MAP2K5-LBXCOR1 locus among 18 new BMI-associated regions in a meta-analysis of 249,796 individuals — the largest BMI GWAS at the time. The signal confirmed 14 previously known obesity loci and newly implicated MAP2K5 in body weight regulation.

A replication study in children⁸⁸ replication study in children
Rask-Andersen et al. The MAP2K5-linked SNP rs2241423 is associated with BMI and obesity in two cohorts of Swedish and Greek children. BMC Med Genet, 2012 confirmed the association in two independent European pediatric cohorts. The A (minor) allele showed a protective effect against obesity in Swedish children (OR 0.79, P = 0.029) and was associated with lower BMI z-scores in Greek children (P = 0.028). Notably, the effect appears stronger in children than adults, suggesting MAP2K5 may be particularly important during developmental adipogenesis.

A fine-mapping study⁹⁹ fine-mapping study
Lu et al. Fine mapping of the MAP2K5 region identified rs7175517 as a causal variant related to BMI in China and the United Kingdom populations. Front Genet, 2022 using UK Biobank and Chinese cohort data identified the molecular mechanism: the G allele at the causal SNP reduces MAP2K5 expression by altering spliceosome binding, leading to reduced MEK5 protein and enhanced adipogenesis. The effect was consistent across European and East Asian populations.

Practical Actions

Since MAP2K5 affects adipogenesis — the formation of new fat cells — rather than the size of existing ones, interventions that modulate fat cell formation pathways are more relevant than simple calorie restriction. Once formed, fat cells persist for years and are difficult to eliminate. This makes prevention of excessive adipogenesis during critical periods (childhood, puberty, periods of weight gain) particularly important.

Interactions

MAP2K5 sits in the adipogenesis pathway that was highlighted by the Shungin et al. 2015 GWAS as a key process in fat distribution. The MEK5-ERK5 axis intersects with PPARG signaling (rs1801282), since PPARG is the master transcription factor driving terminal adipocyte differentiation. Carriers of risk alleles at both MAP2K5 (enhanced adipogenesis) and PPARG (altered adipocyte maturation) may have compounded effects on fat cell biology.

At the tips of every chromosome sit telomeres — repetitive DNA sequences that protect the genome from erosion with each cell division. Maintaining these caps requires more than the enzyme telomerase; it requires a specialized helicase called RTEL1¹¹ RTEL1
Regulator of Telomere Elongation Helicase 1 — a DNA helicase essential for resolving structural barriers that arise at telomeres during replication and repair. RTEL1 dismantles T-loops (protective hairpin structures formed at telomere ends), resolves G-quadruplex structures that form in the guanine-rich telomeric sequence, and participates broadly in genome-wide DNA repair. rs2297440 is a common intronic variant at the RTEL1 locus on chromosome 20q13.33 that has been associated with altered glioma susceptibility across multiple populations — a signal most plausibly explained by differences in telomere maintenance capacity and genomic stability.

The Mechanism

As an intronic variant, rs2297440 does not change the RTEL1 protein sequence directly. Rather, it tags a haplotype within the RTEL1 gene that may influence expression levels, splicing efficiency, or regulatory element function in specific cell types — particularly neural progenitor cells and immune cells, where telomere maintenance is critical for clonal expansion and self-renewal. RTEL1 protein is required at two distinct points during the cell cycle: it opens the T-loop to allow telomerase access for elongation, and it suppresses aberrant homologous recombination across telomeric repeats that would otherwise generate extrachromosomal telomere circles (T-circles) and drive telomere instability. Reduced RTEL1 function — even heterozygous reduction — produces measurable increases in T-circle formation²² T-circle formation
T-circles are circular telomere DNA molecules generated when the T-loop is aberrantly excised; their accumulation is a marker of telomere instability and accelerated telomere shortening and shortened peripheral blood telomere length. In the immune compartment, telomere shortening limits lymphocyte proliferative capacity and accelerates immune aging, a process implicated in inflammaging — the chronic low-grade inflammation that underlies multiple age-related diseases.

The Evidence

The chromosome 20q13.33 RTEL1 locus was first identified as a glioma susceptibility locus through European GWAS, with multiple SNPs across the locus — including rs2297440 and rs6010620 — reaching genome-wide significance. A case-control study in 629 Chinese glioma patients and 645 controls³³ case-control study in 629 Chinese glioma patients and 645 controls found rs2297440 significantly associated with glioma risk (OR 1.33, 95% CI 1.12–1.58, p=0.001); the CC genotype (homozygous for the C/non-T allele) was strongly protective (OR 0.47, 95% CI 0.31–0.71, p=0.0003), while the T allele consistently appeared at higher frequency in cases. A meta-analysis⁴⁴ meta-analysis pooling multiple case-control studies confirmed the rs2297440 T allele confers significantly elevated glioma risk across European, Asian, and American subgroups, supporting its biological rather than population-specific relevance.

Beyond glioma, the RTEL1 locus connects to pulmonary biology. A case-control study of high-altitude pulmonary edema⁵⁵ case-control study of high-altitude pulmonary edema
HAPE — a life-threatening non-inflammatory pulmonary edema triggered by hypoxic stress; SNPs in RTEL1 were associated with altered susceptibility, implicating telomere maintenance in pulmonary vascular response found RTEL1 variants associated with HAPE risk in Chinese populations. More clinically, heterozygous rare RTEL1 mutations — at the severe end of the same functional spectrum — account for approximately 6% of familial pulmonary fibrosis⁶⁶ 6% of familial pulmonary fibrosis
IPF — idiopathic pulmonary fibrosis; a progressive, fatal lung scarring disease linked to short telomeres in alveolar epithelial cells families, establishing that the RTEL1 telomere-maintenance axis is directly implicated in fibrotic pulmonary inflammation. Related RTEL1 variants (rs2297441, rs3208008) have been shown to influence both leukocyte telomere length and prostate cancer risk⁷⁷ both leukocyte telomere length and prostate cancer risk
A Chinese case-control study demonstrated that RTEL1 variants associating with shorter telomeres also associate with increased cancer susceptibility, supporting telomere length as the mechanistic intermediate, pointing to telomere length as the intermediate phenotype linking RTEL1 variation to diverse cancer and inflammatory outcomes.

Practical Actions

The T allele's risk is primarily genomic stability–mediated: reduced RTEL1 helicase efficiency allows telomere erosion in rapidly dividing cells. Supporting telomere maintenance biochemically — particularly through antioxidant pathways that reduce oxidative damage to telomere repeats — is the most actionable intervention. Folate-dependent one-carbon metabolism is directly linked to telomere maintenance: folate drives the synthesis of nucleotides needed for telomere repair, and inadequate folate status accelerates telomere shortening independently of RTEL1 function. Periodic monitoring of telomere length via clinical testing is emerging as a practical option for T-allele carriers concerned about their genomic aging trajectory.

Interactions

rs2297440 shares a haplotype block with rs6010620, which shows nearly identical associations with glioma risk in most studies (OR 1.32, 95% CI 1.11–1.56 in the same Chinese cohort). Carriers of risk alleles at both SNPs likely have the highest risk at this locus. Related variants rs2297441 and rs3208008 influence telomere length in independent analyses and may compound the effect of rs2297440 on telomere maintenance capacity. Given the biological mechanism, variants in other telomere biology genes — TERT, TERC, OBFC1 — may interact additively: polygenic telomere length scores that incorporate RTEL1 variants have been shown to associate with cancer susceptibility and longevity outcomes.